Phase I/II trial of S-1+Nedaplatin+Cetuximab for recurrent/metastatic head and neck squamous cell carcinoma
Latest Information Update: 18 May 2016
At a glance
- Drugs Cetuximab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Nedaplatin (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- 26 Nov 2015 Status changed from planning to completed.
- 21 Nov 2013 New trial record